Biocartis, Kite Sign Development Agreement for Immunotherapy Assays

Jun 03, 2019

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced on Saturday that it has signed a master development and commercialization agreement with Gilead Sciences subsidiary Kite to develop molecular-based assays on its Idylla platform that support Kite's therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Menu

Biocartis, Kite Sign Development Agreement for Immunotherapy Assays

To read the full story....

Breaking News

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations

FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

Multi-Gene Panel Testing Finds Pathogenic Variant Carriers Missed Under Current Testing Guidelines

Saga Diagnostics Raises $4.2M

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

What's Popular?

Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms

Wake Forest Researchers Learn From Patient Data in Offering Precision Oncology Broadly

ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

Sponsorships